Boston Scientific (NYSE:BSX) has halted the use of certain AXIOS Stent and Electrocautery-Enhanced Delivery Systems following reports of deployment complications linked to serious injuries and deaths. As of December 23, the company reported 167 serious injuries and 3 deaths associated with the issue. The FDA advised customers to stop using and remove remaining inventory from circulation on December 19, 2025.

The global neuromodulation devices market is projected to grow from USD 7.8 billion in 2024 to USD 16.1 billion by 2032, driven by increasing prevalence of chronic neurological conditions, technological innovations, and supportive regulatory frameworks. North America leads with 55% market share, while Asia-Pacific emerges as the fastest-growing region with over 12% CAGR. Recent FDA approvals include ProlivRx for depression treatment and Medtronic's adaptive deep brain stimulation system for Parkinson's disease.

The global rigid endoscopes market is projected to grow from USD 7.36 billion in 2025 to USD 11.52 billion by 2033, at a CAGR of 5.84%. Growth is driven by technological advancements in HD and 4K imaging, increasing adoption of minimally invasive procedures across multiple surgical specialties, and the rapid expansion of ambulatory surgery centers. North America leads with 41% market share, while Asia-Pacific is expected to register the highest growth rate at 8.00%.

The global Pulmonary Artery Catheter Market is valued at USD 1.23 billion in 2025 and is projected to reach USD 1.97 billion by 2035, growing at a CAGR of 4.87%. Growth is driven by increasing critical care procedures, rising cardiovascular disease prevalence, expanding ICU capacities, and demand for precise hemodynamic monitoring. The U.S. market is expected to grow from USD 0.38 billion to USD 0.58 billion during the same period.

The global uterine fibroid market is projected to grow from USD 5.26 billion in 2025 to USD 9.43 billion by 2033 at a CAGR of 7.63%. Growth is driven by rising prevalence of fibroids (affecting 70-80% of women by age 50), technological advances in minimally invasive procedures with 60% adoption increase, and expanded healthcare infrastructure in emerging markets. Minimally invasive procedures and MRI-guided focused ultrasound are expected to see the fastest growth rates.

Royal Philips-coordinated SEISMIC research consortium has secured EUR 23.5 million in EU funding to develop minimally invasive neurosurgical techniques combined with advanced imaging technologies. The five-year program, with total budget of EUR 38.4 million, involves nine medical technology companies and seven academic institutions, focusing on treating intracerebral hemorrhage, subdural hematoma, and brain tumors through innovative approaches including real-time ultrasound-guided procedures and cryoablation.

The global surgical staplers market is projected to grow from USD 6.41 billion in 2025 to USD 10.87 billion by 2033, at a CAGR of 6.87%. Growth is driven by increasing surgical volumes, adoption of minimally invasive procedures, and technological advancements in powered and disposable stapling systems. However, high device costs and stringent regulatory requirements pose challenges to market expansion.

Boston Scientific stock plummeted 17.5% on February 4, 2026, despite beating Q4 earnings expectations with 16% sales growth and 14% adjusted EPS growth. The sharp decline was driven by cautious 2026 guidance that fell one penny short of analyst expectations and weaker electrophysiology sales. The analyst argues the market reaction is overdone, citing strong fundamentals including $4.2 billion projected free cash flow for 2026 and 12 consecutive quarters of double-digit sales growth.

Boston Scientific reported Q4 2025 results that beat expectations with $5.29B in revenue and $0.80 adjusted EPS. However, the stock plummeted 15.76% to a 52-week low due to a soft 2026 guidance (10.5%-11.5% growth) and an FDA safety issue involving AXIOS stents that caused 167 serious injuries and 3 deaths, prompting a recall.

The global transcatheter embolization and occlusion devices market is projected to grow from USD 5.93 billion in 2025 to USD 11.53 billion by 2033, expanding at a CAGR of 8.66%. Growth is driven by increasing adoption of minimally invasive procedures in oncology and neurovascular interventions, with North America leading at 38.12% market share and Asia Pacific showing the fastest growth at 9.25% CAGR.

Boston Scientific has issued a recall of certain AXIOS stents and electrocautery-enhanced delivery systems due to deployment and expansion difficulties. As of December 23, the company reported 167 serious injuries and 3 deaths associated with the issue. The FDA is actively reviewing the potentially high-risk device issue. The complications occur during delivery, not after implantation.

The global synthetic absorbable sutures market is valued at USD 2.51 billion in 2025 and is projected to reach USD 4.36 billion by 2033, growing at a CAGR of 7.19%. Growth is driven by rising surgical volumes, increasing adoption of minimally invasive procedures, and advancements in polymer technology. However, higher costs compared to conventional sutures may limit adoption in cost-sensitive markets. North America leads with 40% market share, while Asia Pacific is expected to grow fastest at 9.31% CAGR.